Stemline Targeting cancer at its root
developing novel drugs that attack Cancer Stem Cells

Investor Relations


$15.49 - 1.09
Volume: 133,100
Apr 27, 2015 4:00 PM ET
Delayed at least 20min., by eSignal.

Stock price graph

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel therapeutics targeting both cancer stem cells (CSCs) and tumor bulk. Stemline is currently developing two clinical stage product candidates, SL-401 and SL-701, and a pipeline of preclinical candidates including SL-801 and SL-501.

SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) present on CSCs and tumor bulk of a wide range of hematologic cancers. Three multicenter clinical trials with SL-401 are currently open in the following indications: 1) blastic plasmacytoid dendritic cell neoplasm (BPDCN) and relapsed/refractory acute myeloid leukemia (AML), the expansion stage of which we have designed to serve as the registration trial for BPDCN; 2) AML patients in first complete remission (CR) with minimal residual disease (MRD); and 3) four types of advanced high-risk myeloproliferative neoplasms (MPN), including systemic mastocytosis, advanced symptomatic hypereosinophilic disorder, myelofibrosis, and chronic myelomonocytic leukemia. Additional SL-401 studies are currently planned in myeloma and certain other lymphomas and leukemias. Previously, SL-401 demonstrated single-agent activity, including multiple durable complete responses (CRs), in a Phase 1/2 trial in several indications including BPDCN and relapsed/refractory AML.

SL-701 is an enhanced immunotherapy designed to activate the immune system to attack tumors. A multicenter clinical trial with SL-701 is currently open and accruing adult patients with glioblastoma multiforme (GBM) in first recurrence. Additional SL-701 studies are currently planned in pediatric high-grade glioma. Previously, an earlier version of the therapy demonstrated clinical activity, including durable CRs and partial responses (PRs), in Phase 1/2 trials in adults and children with advanced brain cancers.

Preclinical candidates being advanced toward investigational new drug (IND) filings include SL-801 , a novel, oral small molecule reversible inhibitor of XPO1, being developed for solid and hematologic cancers, and SL-501, a next generation IL-3R targeted therapy, being developed for oncologic and certain autoimmune indications.

Corporate Snapshot

PDF Corporate Snapshot

Corporate Presentation

PDF Corporate Presentation March 2015

View all »   RSSRecent Releases

Mar 13, 2015
Stemline Therapeutics Reports Fourth Quarter 2014 Financial Results

Mar 6, 2015
Stemline Therapeutics to Present at the 27th Annual ROTH Conference

View all »Events & Presentations

There are no upcoming events at this moment.

Copyright 2015 - Stemline Therapeutics, Inc. All rights reserved